QUEBEC CITY, July 17 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that it will be presenting an overview of its development of
vaccines generated from plant-made Virus-Like Particles and unique technology
platform at the Next Generation Vaccines 2008 Conference, held from July
17-18, 2008, at the Gaylord National Resort and Convention Center, National
Sonia Trepanier, Ph.D., Project Manager, Product Development will deliver
a presentation on "An Innovative VLP-Based Technology for a Rapid and
Efficient Pandemic Response," in a session entitled "Development and
Manufacturing of BioDefense Vaccines," on Friday July 18, 2008 at 11:30 a.m.
Additional information about the Next Generation Vaccines 2008
Conference, including the full scientific program, can be viewed at
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release.
For further information:
For further information: Contact: Medicago, Inc., Andy Sheldon,
President and CEO, (418) 658-9393; Investor relations: The Equicom Group Inc.,
Arianna Vanin, (514) 844-4680, email@example.com